- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
R&D
Lilly stops development on cancer drug after failed study
May 10, 2013
Bloomberg NewsThe drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual
sales by 2018.
MoreIU medical school's push to launch startups bears fruit
April 13, 2013
J.K. WallThe Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity
the school has never seen before.
MoreJ&J wins OK for first in new class of diabetes drugs
March 31, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family
of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
MoreLilly, Boehringer submit diabetes drug to FDA
March 25, 2013
Associated PressEli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker
Boehringer Ingelheim to the Food and Drug Administration.
MoreCourt may decide if drugmakers can pay to delay generics
March 25, 2013
Associated PressFederal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors
to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for
years, steep price declines.
MoreEndocyte stock sinks due to possible drug-filing delay
February 26, 2013
J.K. WallEndocyte Inc. saw its shares fall nearly 7 percent Tuesday morning after the drug development firm announced that its application
for U.S. approval of a cancer drug could be delayed another 10 months.
MoreLilly halts late-stage testing of rheumatoid arthritis drug
February 7, 2013
Bloomberg NewsEli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective.
The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
MoreLilly finds solace in new Alzheimer's study
December 17, 2012
J.K. WallEli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published
new research that the pharmaceutical company thinks confirms it is on the right track.
MoreLilly chief says China too slow in approving new drugs
November 28, 2012
Bloomberg NewsChina takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at
ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
MoreDrugmakers collaborate to facilitate drug tests
November 15, 2012
Associated PressEli Lilly and Co. and two other major drugmakers say they are collaborating in a global project aimed at getting patient tests
of experimental drugs up and running more quickly and efficiently.
MoreLilly, Roche drugs chosen for Alzheimer’s prevention trial
October 10, 2012
Bloomberg NewsEli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s
trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
MoreGroup aims to cut costs of late-stage drugs
September 24, 2012
J.K. WallYou know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help.
But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs
out of clinical trials.
MoreLilly stops testing of experimental schizophrenia drug
August 29, 2012
Bloomberg NewsEli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was
unlikely to show a benefit in patients.
MoreAlzheimer's quest puts Lilly to test
August 11, 2012
J.K. WallOdds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results
are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a
home run for Lilly.
MorePotential Lilly antipsychotic falls short in study
July 11, 2012
Associated PressEli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking
the drug to those taking a placebo.
MoreGood cholesterol may not lower heart risk, study suggests
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
MoreRoche scraps hoped-for cholesterol blockbuster
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
MoreLilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
MoreEndocyte could get $1B from Merck development deal
April 16, 2012
Associated PressEndocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian
cancer treatment with pharmaceutical giant Merck & Co.
MoreEndocyte pulls trigger on European drug submission
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
MoreFDA removes hurdle in Endocyte's path to drug approval
March 5, 2012
J.K. WallEndocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced
Monday, clearing away a hurdle to getting the drug approved in Europe.
MoreLechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MorePressure rises as Lilly tries squeeze play
January 9, 2012
J.K. WallIndianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire,
even as the company needs to spend more money on marketing and research to boost sales of new drugs.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MoreEndocyte shares plunge on clinical trial results
December 13, 2011
J.K. WallShares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s
experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.